Raymond Woo Sells 1,966 Shares of CeriBell (NASDAQ:CBLL) Stock

CeriBell, Inc. (NASDAQ:CBLL) CTO Raymond Woo sold 1,966 shares of CeriBell stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $18.00, for a total transaction of $35,388.00. Following the completion of the transaction, the chief technology officer owned 195,682 shares in the company, valued at approximately $3,522,276. This trade represents a 0.99% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Raymond Woo also recently made the following trade(s):

• On Friday, May 1st, Raymond Woo sold 11,104 shares of CeriBell stock. The shares were sold at an average price of $20.44, for a total transaction of $226,965.76.
• On Wednesday, April 1st, Raymond Woo sold 11,112 shares of CeriBell stock. The shares were sold at an average price of $18.56, for a total transaction of $206,238.72.
• On Monday, March 2nd, Raymond Woo sold 8,087 shares of CeriBell stock. The shares were sold at an average price of $18.25, for a total transaction of $147,587.75.

CeriBell Stock Performance

NASDAQ:CBLL opened at $18.70 on Thursday. The firm’s fifty day moving average price is $19.08 and its 200 day moving average price is $19.29. CeriBell, Inc. has a 1-year low of $10.85 and a 1-year high of $24.33. The company has a debt-to-equity ratio of 0.14, a current ratio of 10.44 and a quick ratio of 10.01. The firm has a market cap of $709.48 million, a price-to-earnings ratio of -11.47 and a beta of 0.99.

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.13). CeriBell had a negative net margin of 63.51% and a negative return on equity of 38.19%. The firm had revenue of $26.49 million during the quarter, compared to analysts’ expectations of $26.09 million. On average, sell-side analysts expect that CeriBell, Inc. will post -1.69 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have commented on CBLL. BTIG Research restated a “buy” rating and set a $30.00 target price on shares of CeriBell in a research report on Wednesday, January 28th. Weiss Ratings lowered shares of CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, May 12th. Finally, Canaccord Genuity Group decreased their target price on shares of CeriBell from $28.00 to $25.00 and set a “buy” rating on the stock in a research report on Tuesday, May 12th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, CeriBell has an average rating of “Moderate Buy” and a consensus target price of $22.20.

Institutional Investors Weigh In On CeriBell

Several institutional investors have recently made changes to their positions in CBLL. Strs Ohio purchased a new stake in shares of CeriBell during the 1st quarter worth $27,000. Caitong International Asset Management Co. Ltd boosted its position in shares of CeriBell by 3,971.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock worth $28,000 after purchasing an additional 1,231 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of CeriBell during the 3rd quarter worth $33,000. CWM LLC raised its stake in shares of CeriBell by 1,178.5% during the 4th quarter. CWM LLC now owns 1,841 shares of the company’s stock worth $40,000 after buying an additional 1,697 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its stake in shares of CeriBell by 353.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock worth $43,000 after buying an additional 1,801 shares during the last quarter.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.